289 related articles for article (PubMed ID: 19077243)
1. Highly variable response to cytotoxic chemotherapy in carcinoma-associated fibroblasts (CAFs) from lung and breast.
Sonnenberg M; van der Kuip H; Haubeis S; Fritz P; Schroth W; Friedel G; Simon W; Mürdter TE; Aulitzky WE
BMC Cancer; 2008 Dec; 8():364. PubMed ID: 19077243
[TBL] [Abstract][Full Text] [Related]
2. Cancer cells cue the p53 response of cancer-associated fibroblasts to cisplatin.
Schmid JO; Dong M; Haubeiss S; Friedel G; Bode S; Grabner A; Ott G; Mürdter TE; Oren M; Aulitzky WE; van der Kuip H
Cancer Res; 2012 Nov; 72(22):5824-32. PubMed ID: 22962266
[TBL] [Abstract][Full Text] [Related]
3. Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel.
Chrisanthar R; Knappskog S; Løkkevik E; Anker G; Ostenstad B; Lundgren S; Risberg T; Mjaaland I; Skjønsberg G; Aas T; Schlichting E; Fjösne HE; Nysted A; Lillehaug JR; Lønning PE
PLoS One; 2011 Apr; 6(4):e19249. PubMed ID: 21556366
[TBL] [Abstract][Full Text] [Related]
4. Candidate markers that associate with chemotherapy resistance in breast cancer through the study on Taxotere-induced damage to tumor microenvironment and gene expression profiling of carcinoma-associated fibroblasts (CAFs).
Rong G; Kang H; Wang Y; Hai T; Sun H
PLoS One; 2013; 8(8):e70960. PubMed ID: 23951052
[TBL] [Abstract][Full Text] [Related]
5. Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation.
Yoshida T; Ishii G; Goto K; Neri S; Hashimoto H; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Iida S; Niimi A; Nagai K; Ohe Y; Ochiai A
Clin Cancer Res; 2015 Feb; 21(3):642-51. PubMed ID: 25388165
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer-associated fibroblasts induce epithelial-to-mesenchymal transition in breast cancer cells.
Soon PS; Kim E; Pon CK; Gill AJ; Moore K; Spillane AJ; Benn DE; Baxter RC
Endocr Relat Cancer; 2013 Feb; 20(1):1-12. PubMed ID: 23111755
[TBL] [Abstract][Full Text] [Related]
7. Imatinib mesylate inhibits the proliferation-stimulating effect of human lung cancer-associated stromal fibroblasts on lung cancer cells.
Kinoshita K; Nakagawa K; Hamada J; Hida Y; Tada M; Kondo S; Moriuchi T
Int J Oncol; 2010 Oct; 37(4):869-77. PubMed ID: 20811709
[TBL] [Abstract][Full Text] [Related]
8. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy.
Ryu JS; Hong YC; Han HS; Lee JE; Kim S; Park YM; Kim YC; Hwang TS
Lung Cancer; 2004 Jun; 44(3):311-6. PubMed ID: 15140544
[TBL] [Abstract][Full Text] [Related]
9. ER-activating ability of breast cancer stromal fibroblasts is regulated independently of alteration of TP53 and PTEN tumor suppressor genes.
Suda T; Oba H; Takei H; Kurosumi M; Hayashi S; Yamaguchi Y
Biochem Biophys Res Commun; 2012 Nov; 428(2):259-63. PubMed ID: 23068099
[TBL] [Abstract][Full Text] [Related]
10. Stromal-MDM2 Promotes Lung Cancer Cell Invasion through Tumor-Host Feedback Signaling.
Kamer I; Daniel-Meshulam I; Zadok O; Bab-Dinitz E; Perry G; Feniger-Barish R; Perelman M; Barshack I; Ben-Nun A; Onn A; Bar J
Mol Cancer Res; 2020 Jun; 18(6):926-937. PubMed ID: 32169890
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of PAI-1 limits chemotherapy resistance in lung cancer through suppressing myofibroblast characteristics of cancer-associated fibroblasts.
Masuda T; Nakashima T; Namba M; Yamaguchi K; Sakamoto S; Horimasu Y; Miyamoto S; Iwamoto H; Fujitaka K; Miyata Y; Hamada H; Okada M; Hattori N
J Cell Mol Med; 2019 Apr; 23(4):2984-2994. PubMed ID: 30734495
[TBL] [Abstract][Full Text] [Related]
12. Ercc1 Deficiency Promotes Tumorigenesis and Increases Cisplatin Sensitivity in a Tp53 Context-Specific Manner.
Jokić M; Vlašić I; Rinneburger M; Klümper N; Spiro J; Vogel W; Offermann A; Kümpers C; Fritz C; Schmitt A; Riabinska A; Wittersheim M; Michels S; Ozretić L; Florin A; Welcker D; Akyuz MD; Nowak M; Erkel M; Wolf J; Büttner R; Schumacher B; Thomale J; Persigehl T; Maintz D; Perner S; Reinhardt HC
Mol Cancer Res; 2016 Nov; 14(11):1110-1123. PubMed ID: 27514406
[TBL] [Abstract][Full Text] [Related]
13.
Karekla E; Liao WJ; Sharp B; Pugh J; Reid H; Quesne JL; Moore D; Pritchard C; MacFarlane M; Pringle JH
Cancer Res; 2017 Apr; 77(8):2029-2039. PubMed ID: 28202521
[TBL] [Abstract][Full Text] [Related]
14. [Association of the responsiveness of advanced non-small cell lung cancer to platinum-based chemotherapy with p53 and p73 polymorphisms].
Yuan P; Miao XP; Zhang XM; Wang ZH; Tan W; Zhang XR; Sun Y; Xu BH; Lin DX
Zhonghua Zhong Liu Za Zhi; 2006 Feb; 28(2):107-10. PubMed ID: 16750013
[TBL] [Abstract][Full Text] [Related]
15. Reprogramming carcinoma associated fibroblasts by AC1MMYR2 impedes tumor metastasis and improves chemotherapy efficacy.
Ren Y; Zhou X; Liu X; Jia HH; Zhao XH; Wang QX; Han L; Song X; Zhu ZY; Sun T; Jiao HX; Tian WP; Yang YQ; Zhao XL; Zhang L; Mei M; Kang CS
Cancer Lett; 2016 Apr; 374(1):96-106. PubMed ID: 26872723
[TBL] [Abstract][Full Text] [Related]
16. Association of the germline TP53 R72P and MDM2 SNP309 variants with breast cancer survival in specific breast tumor subgroups.
van den Broek AJ; Broeks A; Horlings HM; Canisius SV; Braaf LM; Langerød A; Van't Veer LJ; Schmidt MK
Breast Cancer Res Treat; 2011 Nov; 130(2):599-608. PubMed ID: 21667122
[TBL] [Abstract][Full Text] [Related]
17. MDM2 rs2279744 and TP53 rs1042522 polymorphisms associated with etoposide- and cisplatin-induced grade III/IV neutropenia in Chinese extensive-stage small-cell lung cancer patients.
Wang X; Wang YZ; Ma KW; Chen X; Li W
Oncol Res Treat; 2014; 37(4):176-80. PubMed ID: 24732641
[TBL] [Abstract][Full Text] [Related]
18. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients.
Kandioler-Eckersberger D; Ludwig C; Rudas M; Kappel S; Janschek E; Wenzel C; Schlagbauer-Wadl H; Mittlböck M; Gnant M; Steger G; Jakesz R
Clin Cancer Res; 2000 Jan; 6(1):50-6. PubMed ID: 10656431
[TBL] [Abstract][Full Text] [Related]
19. p53 in breast cancer subtypes and new insights into response to chemotherapy.
Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
[TBL] [Abstract][Full Text] [Related]
20. Novel module and hub genes of distinctive breast cancer associated fibroblasts identified by weighted gene co-expression network analysis.
Xu Y; Zhang Z; Zhang L; Zhang C
Breast Cancer; 2020 Sep; 27(5):1017-1028. PubMed ID: 32383139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
